Drug Profile
AT 101 - AbClon
Alternative Names: AT-101 - AbClon; AT101Latest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator AbClon
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
Most Recent Events
- 09 Dec 2023 Adverse events and efficacy data from a phase-I/II trial in Non Hodgkin Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 02 Jun 2023 Updated adverse events and efficacy data from a phase I/II trial in Non Hodgkin Lymphoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 17 Apr 2023 AbClon completes patent filing for technologies applied for AT 101 in USA, Canada, Japan, and South Korea